2.55
price up icon2.82%   0.07
after-market Dopo l'orario di chiusura: 2.55
loading
Precedente Chiudi:
$2.48
Aprire:
$2.59
Volume 24 ore:
956.48K
Relative Volume:
0.59
Capitalizzazione di mercato:
$279.77M
Reddito:
-
Utile/perdita netta:
$-134.24M
Rapporto P/E:
-1.4407
EPS:
-1.77
Flusso di cassa netto:
$-121.34M
1 W Prestazione:
+8.97%
1M Prestazione:
+4.08%
6M Prestazione:
-38.26%
1 anno Prestazione:
-58.13%
Intervallo 1D:
Value
$2.49
$2.6784
Intervallo di 1 settimana:
Value
$2.2104
$2.6784
Portata 52W:
Value
$1.285
$7.85

Annexon Inc Stock (ANNX) Company Profile

Name
Nome
Annexon Inc
Name
Telefono
(650)-822-5500
Name
Indirizzo
1400 SIERRA POINT PARKWAY, BRISBANE
Name
Dipendente
100
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
ANNX's Discussions on Twitter

Confronta ANNX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ANNX
Annexon Inc
2.55 260.02M 0 -134.24M -121.34M -1.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Annexon Inc Stock (ANNX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-03-01 Aggiornamento JP Morgan Neutral → Overweight
2023-12-21 Aggiornamento BofA Securities Neutral → Buy
2023-10-30 Iniziato Wells Fargo Overweight
2023-05-26 Downgrade BofA Securities Buy → Neutral
2023-05-25 Downgrade JP Morgan Overweight → Neutral
2022-09-16 Iniziato Jefferies Buy
2022-09-09 Iniziato BTIG Research Buy
2021-11-30 Iniziato H.C. Wainwright Buy
2021-09-23 Iniziato Cantor Fitzgerald Overweight
2021-01-26 Iniziato Needham Buy
2020-08-18 Iniziato BofA Securities Buy
2020-08-18 Iniziato Cowen Outperform
2020-08-18 Iniziato JP Morgan Overweight
Mostra tutto

Annexon Inc Borsa (ANNX) Ultime notizie

pulisher
Jul 24, 2025

Annexon Inc. Stock Analysis and ForecastOutperformance with explosive growth - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy - Ophthalmology Times

Jul 24, 2025
pulisher
Jul 24, 2025

Annexon completes enrollment for phase 3 dry AMD therapy trial - Investing.com Australia

Jul 24, 2025
pulisher
Jul 24, 2025

Annexon, Inc. Completes Enrollment of Phase 3 ARCHER II Trial for Vonaprument, Targeting Vision Preservation in Dry AMD with Geographic Atrophy - Nasdaq

Jul 24, 2025
pulisher
Jul 24, 2025

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Annexon Inc. stockBreakout portfolio performance - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Annexon Inc. stock priceRapidly expanding wealth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Annexon Inc. a good long term investmentHigh-performance investment picks - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Why Annexon Inc. stock attracts strong analyst attentionCapital Doubling Tips - Newser

Jul 22, 2025
pulisher
Jul 18, 2025

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - 富途牛牛

Jul 18, 2025
pulisher
Jul 18, 2025

Is Annexon Inc. stock a growth or value playHigh Reward Risk Balanced Trading - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Annexon Inc (ANNX) Stock: A Comprehensive 52-Week Review - investchronicle.com

Jul 17, 2025
pulisher
Jul 16, 2025

Annexon EVP Yednock sells $2.9k in shares By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 16, 2025

Annexon EVP Yednock sells $2.9k in shares - Investing.com Australia

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Annexon Inc. stock price move sharplyTop Performing Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Annexon Inc. stock performs during market volatilityWeekly Big Movers - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Annexon: Lead GBS Therapy Stokes Near Term Potential (NASDAQ:ANNX) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 11, 2025

Annexon Target of Unusually Large Options Trading (NASDAQ:ANNX) - Defense World

Jul 11, 2025
pulisher
Jul 09, 2025

Annexon (NASDAQ:ANNX) Stock Price Down 0.7% – Should You Sell? - Defense World

Jul 09, 2025
pulisher
Jul 07, 2025

Annexon, Inc. shares rise 2.08% premarket after Apogee Therapeutics announces Phase 2 trial results. - AInvest

Jul 07, 2025
pulisher
Jun 18, 2025

Annexon says enrollment of Phase 3 Archer II Trial expected to be completed in Q3 2025 - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrop - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) - GlobeNewswire

Jun 18, 2025
pulisher
Jun 17, 2025

Bank of America Corp DE Sells 137,220 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World

Jun 17, 2025

Annexon Inc Azioni (ANNX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):